Graves Orbitopathy
📧 Sign up to get email alerts when something new happens for Graves Orbitopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-26Clinical Trial Results: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]
Phase 2b/Phase 3 clinical trial results for linsitinib in active moderate to severe thyroid eye disease (Graves orbitopathy).
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease [Phase 2]
Phase 2 clinical trial update on tofacitinib for glucocorticoid-resistant moderate-to-severe Thyroid Eye Disease; the study is currently act…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Development of a Non-Invasive Prognostic Test for Graves Orbitopathy [NA]
Clinical trial update describing the development of a non-invasive prognostic test for Graves' orbitopathy, sponsored by University Hospital…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Changes in Orbital Macrovascular and Intraocular Microvascular Blood Flow After Orbital Decompression Surgery in Patients With Thyroid Eye Disease [NA]
Clinical trial update reporting changes in orbital macrovascular and intraocular microvascular blood flow after orbital decompression surger…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
This recruiting clinical trial studies the progression of inflammatory orbitopathy (Graves' orbitopathy) and the biological progression of p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]
This document notes an ongoing Phase 2b/Phase 3 trial evaluating linsitinib for Thyroid Eye Disease, currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) [Phase 3]
A Phase 3 trial evaluating secukinumab 300 mg for Thyroid Eye Disease (Graves' orbitopathy) was terminated, and results have been posted.
-
CLINICAL_TRIALS research · 2024-06-20Clinical Trial Update: Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
Amgen's expanded access protocol for Teprotumumab (HZN-001) to treat active thyroid eye disease (Graves' orbitopathy) has been updated; the …
-
FDA approval · 2023-04-13FDA Approved: TEPEZZA — Supplemental Application (Horizon Therapeutics USA, Inc.)
FDA overview of a supplemental application for TEPEZZA (teprotumumab) by Horizon Therapeutics USA, Inc.; the submission status is AP.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy [Phase 3]
Phase 3 clinical trial comparing conservative versus ablative treatment approaches for hyperthyroidism in Graves' Orbitopathy is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-03-15Clinical Trial Update: A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study [Phase 3]
A Phase 3 randomized trial assessing the effects of atorvastatin on Graves' Orbitopathy is listed as not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2021-08-13Clinical Trial Update: Effects of Atorvastatin in Graves' Orbitopathy (GO) [Phase 2]
Phase 2 trial update evaluating the effects of atorvastatin in Graves' orbitopathy (thyroid-associated ophthalmopathy) and hypercholesterole…
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study [Phase 3]
Results from an open-label extension of a Phase 3 trial investigated teprotumumab for Graves' orbitopathy (thyroid eye disease) to determine…
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study [Phase 3]
A Phase 3 randomized, placebo-controlled trial of teprotumumab infusions in Graves' orbitopathy (thyroid eye disease) completed with results…
-
CLINICAL_TRIALS trial_result · 2017-08-14Clinical Trial Update: Graves' Orbitopathy and Hypercholesterolemia
A completed clinical trial sponsored by the University of Pisa investigated Graves' orbitopathy and hypercholesterolemia.
-
CLINICAL_TRIALS research · 2013-12-10Clinical Trial Update: Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy [Phase 2, Phase 3]
A clinical trial update about a Phase 2/Phase 3 study comparing prednisone to doxycycline for Graves' orbitopathy (thyroid-associated ophtha…
-
CLINICAL_TRIALS trial_result · 2013-11-19Clinical Trial Update: Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy
A completed clinical trial update reporting morphometric analysis of orbital structures in Graves' orbitopathy.